ClinicaliQ Trial Snapshot
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue — Recruiting • Phase II • Oncology • NCT06989437.
- Drug being tested: Ponsegromab (a novel therapeutic agent) combined with standard systemic chemotherapy, compared to chemotherapy alone with placebo, in treatment-Phase IIïve patients with metastatic pancreatic ductal adenocarcinoma.
- Patient eligibility overview: Adults with metastatic pancreatic cancer presenting with cachexia (significant involuntary weight loss and fatigue) who have not received prior systemic chemotherapy for advanced disease.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
Eligibility Snapshot
- Key inclusion Criteria: * Signed Informed Consent Document * Documented active diagnosis of metastatic pancreatic ductal adenocarcinoma * Cachexia defined by Fearon criteria of weight loss * Completed 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy or 2 x 14-day cycles of FOLFIRINOX chemotherapy and prior to receiving Cycle 2 chemotherapy * ECOG PS ≤1 with life expectancy of at least 4 months Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.